Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.60 |
| ▸ | CDK9 | P50750 | 2/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.58 |
| ▸ | CDK1 | P06493 | 6/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.56 |
| ▸ | PRKACA | P17612 | 1/20 | 0.56 |
| ▸ | PRKACG | P22612 | 1/20 | 0.56 |
| ▸ | PRKACB | P22694 | 1/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13057359 | 0.95 | CDK2 (0.61) | CDK2CDK9CCNE1CDK1CCNB1 | |
| SCHEMBL31058754 | 0.90 | CDK2 (0.55) | CDK2CDK9CCNE1CDK1CCNB1 | |
| SCHEMBL26772811 | 0.85 | CDK2 (0.61) | CDK2CDK9CCNE1CDK1CCNB1 | |
| SCHEMBL3306974 | 0.84 | CDK2 (0.60) | CDK2CDK9CCNE1CDK1CCNB1 | |
| SCHEMBL13057362 | 0.84 | CDK2 (0.60) | CDK2CDK9CCNE1CDK1CCNB1 | |
| SCHEMBL10169348 | 0.82 | ADORA1 (0.56) | CDK2CCNE1CDK1CCNB1NR1I2 | |
| SCHEMBL13057363 | 0.82 | CDK2 (0.57) | CDK2CDK9CCNE1CDK1CCNB1 | |
| SCHEMBL24707517 | 0.81 | CDK2 (0.67) | CDK2CCNE1CDK1CCNB1CCNA2 | |
| SCHEMBL10082133 | 0.81 | NR1I2 (0.52) | CDK2CDK9CCNE1CDK1CCNB1 | |
| SCHEMBL3130740 | 0.81 | CDK2 (0.56) | CDK2CDK9CCNE1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| US-20210338696-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3865136-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR CORONA VIRUS TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| US-11090316-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190015432-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | EMORY UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-9173893-B2 | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | COCRYSTAL PHARMA, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-7842672-B2 | Phosphonate inhibitors of HCV | GILEAD SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842672-B2 | Phosphonate inhibitors of HCV | GILEAD SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338696-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, GSTO1 | CDK2 2495/4885CDK9 3256/4885CCNE1 2032/4885 |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | CDK2 1244/4885CDK9 194/4885CCNE1 2247/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | CDK2 1244/4885CDK9 194/4885CCNE1 2247/4885 |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | CDK2 1377/4885CDK9 1182/4885CCNE1 958/4885 |
| US-20080107628-A1 | Polymerase inhibitors | POLR2H, POLR2E, POLR1E | CDK2 235/4885CDK9 223/4885CCNE1 891/4885 |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | RNGTT, TYMP, SLC29A1 | CDK2 2350/4885CDK9 1781/4885CCNE1 829/4885 |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, SGMS2 | CDK2 2563/4885CDK9 3309/4885CCNE1 2113/4885 |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | CDK2 831/4885CDK9 782/4885CCNE1 2564/4885 |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | CDK2 831/4885CDK9 782/4885CCNE1 2564/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CDK2 595/4885CDK9 829/4885CCNE1 3249/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CDK2 595/4885CDK9 829/4885CCNE1 3249/4885 |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, GSTO1 | CDK2 2495/4885CDK9 3256/4885CCNE1 2032/4885 |
| US-11090316-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, SGMS2 | CDK2 2563/4885CDK9 3309/4885CCNE1 2113/4885 |
| US-20190015432-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, GSTO1 | CDK2 2495/4885CDK9 3256/4885CCNE1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.